Monte Rosa Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
BOSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue...
Financial
Prometheus Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage biotechnology company pioneering a precision medicine...
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
Sema4|GeneDx President & Chief Executive Officer, Katherine Stueland, to deliver presentationSTAMFORD, Conn., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq:...
Wave Life Sciences Provides Positive Update on Proof-of-Concept Study for WVE-N531 in Duchenne Muscular Dystrophy
53% mean exon skipping and <1% (BLQ) mean dystrophin expression six weeks after initiating biweekly multidosing PN chemistry improved pharmacology...
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY III Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease
Pivotal trial will evaluate efficacy and safety of BXCL501 in Alzheimer’s patients in nursing homes with moderate to severe dementia...
Black Diamond Therapeutics Announces Spinout of Launchpad Therapeutics, Inc., an Antibody-Focused Precision Oncology Company
- $30M Series A investment from Versant Ventures and NEA- CAMBRIDGE, Mass. and NEW YORK, Dec. 12, 2022 (GLOBE NEWSWIRE)...
Asensus Announces Additional Senhance Surgical System Sale
Oncology focused hospital to initiate Senhance System programRESEARCH TRIANGLE PARK, N.C., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Asensus Surgical, Inc....
Prometheus Biosciences Announces Positive Results for PRA023 in Both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a Studies Enabling Pathway to Both First-in-Class and Best-in-Class Anti-TL1A mAb
– ARTEMIS-UC trial met primary endpoint with 26.5% of patients on PRA023 achieving clinical remission compared to 1.5% of patients...
Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors
- Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell...
Symbeo, Inc. launches latest solution for today’s AP challenges
New platform for enterprise and mid-market-size organizations drives invoice automationPORTLAND, Ore., Dec. 06, 2022 (GLOBE NEWSWIRE) -- Symbeo, Inc., a...
Lantern Pharma to Participate at the RHK Capital Disruptive Growth Conference on December 5 at 12:00 p.m. ET
DALLAS, Dec. 02, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Lantern Pharma Inc (Nasdaq: LTRN), a clinical stage biopharmaceutical company using...
International Myeloma Foundation Named Winner of 2022 Amazon Web Services IMAGINE Grant for Nonprofits
The International Myeloma Foundation will work with Amazon’s cloud computing arm to educate patients, understand donors, increase fundraising, and moreSTUDIO...
Syneos Health Releases 2023 Health Trends
Predicts AI and Machine Learning, Diversity and Medical Affairs will Transform Biopharma Product DevelopmentMORRISVILLE, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) --...
BioXcel Therapeutics to Present at Bank of America 2022 Biotech SMID Cap Conference
NEW HAVEN, Conn., Dec. 01, 2022 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
CERIS Expands Services and Rebrands
Rapidly Growing Payment Integrity Firm Offers New Solutions in DRG Validation, Data Mining and More FORT WORTH, Texas, Nov. 29,...
SmileDirectClub Announces Launch of Innovative SmileMaker Platform
Smile-Changing AI Technology Offers View of New Smiles Through Mobile Devices SmileDirectClub SmileMaker Platform The SmileMaker Platform is now available...
Chain Pharmaceuticals GmbH Announces Its Phytocannabinoid Drug Discovery Platform
Company Will Pursue Drug Discovery of Market-Authorized, Finished Pharmaceuticals that Address Demand for Personalized TherapiesFRANKFURT AM MAIN, Germany, Nov. 15,...
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
Company will focus on its high growth, high margin pediatric and rare disease business, powered by whole exome/genome diagnostic testing...
HeartSciences’ MyoVista® Technology Used to Develop AI-ECG Algorithm to Identify Patients at High-Risk of Major Adverse Cardiovascular Events
Independent study demonstrates novel AI-ECG algorithm could provide a cost-effective strategy for improving cardiac risk stratificationSouthlake, Texas, Nov. 10, 2022...
Vyant Bio Teams Up with the International Rett Syndrome Foundation to Host Local Viewing Party in Honor of the 3rd Annual ‘Raise a Glass for Rett Gala’
Charity Event to Drive Awareness and Support Rett Families Around the World CHERRY HILL, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE)...